SG11202002635RA - Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation - Google Patents

Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation

Info

Publication number
SG11202002635RA
SG11202002635RA SG11202002635RA SG11202002635RA SG11202002635RA SG 11202002635R A SG11202002635R A SG 11202002635RA SG 11202002635R A SG11202002635R A SG 11202002635RA SG 11202002635R A SG11202002635R A SG 11202002635RA SG 11202002635R A SG11202002635R A SG 11202002635RA
Authority
SG
Singapore
Prior art keywords
isolating
cancer
cells
methods
specific mutation
Prior art date
Application number
SG11202002635RA
Inventor
Drew C Deniger
Steven A Rosenberg
Parisa Malekzadeh
Original Assignee
The United States Of America As Represented By The Secretary
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America As Represented By The Secretary filed Critical The United States Of America As Represented By The Secretary
Publication of SG11202002635RA publication Critical patent/SG11202002635RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464448—Regulators of development
    • A61K39/46445—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/464451—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG11202002635RA 2017-09-29 2018-09-17 Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation SG11202002635RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762565464P 2017-09-29 2017-09-29
PCT/US2018/051280 WO2019067242A1 (en) 2017-09-29 2018-09-17 Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation

Publications (1)

Publication Number Publication Date
SG11202002635RA true SG11202002635RA (en) 2020-04-29

Family

ID=63763012

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202002635RA SG11202002635RA (en) 2017-09-29 2018-09-17 Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation

Country Status (10)

Country Link
US (1) US20200316121A1 (en)
EP (1) EP3688142A1 (en)
JP (1) JP7391015B2 (en)
KR (1) KR20200065026A (en)
CN (1) CN111344394A (en)
AU (1) AU2018342245B2 (en)
CA (1) CA3080274A1 (en)
IL (1) IL273516A (en)
SG (1) SG11202002635RA (en)
WO (1) WO2019067242A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102375218B1 (en) 2016-12-08 2022-03-17 이매틱스 바이오테크놀로지스 게엠베하 Novel t cell receptors and immune therapy using the same
DE102016123847B3 (en) * 2016-12-08 2018-04-05 Immatics Biotechnologies Gmbh New T cell receptors and their use in immunotherapy
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
AU2018269370A1 (en) 2017-05-16 2019-12-05 The Johns Hopkins University Manabodies and methods of using
US20220332785A1 (en) * 2019-06-27 2022-10-20 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services T cell receptors recognizing r175h or y220c mutation in p53
CN112390875B (en) * 2019-08-16 2023-01-24 香雪生命科学技术（广东）有限公司 High-affinity T cell receptor for identifying AFP
MX2022007598A (en) 2019-12-20 2022-09-23 Instil Bio Uk Ltd Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof.
WO2022051449A2 (en) * 2020-09-04 2022-03-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing r273c or y220c mutations in p53
CN112301088B (en) * 2020-10-21 2022-12-13 杭州纽安津生物科技有限公司 Method for screening neoantigen or neoantigen coding sequence
WO2022183167A1 (en) 2021-02-25 2022-09-01 Alaunos Therapeutics, Inc. Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
KR20230170668A (en) * 2021-03-08 2023-12-19 다이호야쿠힌고교 가부시키가이샤 Cancer treatment in patients with co-occurring genetic alterations in FGFR2 and oncogenic genes
CA3215580A1 (en) * 2021-03-31 2022-10-06 The Johns Hopkins University Methods and materials for targeting tumor antigens
KR20240016288A (en) * 2021-05-07 2024-02-06 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 T cell receptor that recognizes C135Y, R175H, or M237I mutations in p53
CN117980326A (en) 2021-07-14 2024-05-03 2赛文缇生物公司 Engineered T cell receptors fused to binding domains from antibodies
WO2023196996A2 (en) 2022-04-08 2023-10-12 2Seventy Bio, Inc. Multipartite receptor and signaling complexes
WO2024131372A1 (en) * 2022-12-23 2024-06-27 上海市第一人民医院 Tcr targeting cytomegalovirus pp65, t cell expressing tcr and use of t cell
CN116970058B (en) * 2023-09-22 2023-12-15 成都朗谷生物科技股份有限公司 Tumor neoantigen polypeptide aiming at TP53 gene R249S mutation and application thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08501280A (en) * 1992-05-26 1996-02-13 リュクスウニヴェルシテート レイデン Peptides of human p53 protein and human p53 protein-specific cytotoxic T lymphocytes for use in a composition for inducing a human T cell response
JPH0959175A (en) * 1995-06-12 1997-03-04 Meiji Milk Prod Co Ltd Anti-tumor immuno-activating agent
WO2004021995A2 (en) 2002-09-06 2004-03-18 The Government Of The United States Of America, Represented By The Secretary, Departement Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
GB2440736A (en) * 2006-08-10 2008-02-13 Medical Res Council Crystals of mutant p53 polypeptidtes
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
AU2014407540C1 (en) * 2014-10-02 2021-07-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cells having antigenic specificity for a cancer-specific mutation
WO2016053338A1 (en) 2014-10-02 2016-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating t cell receptors having antigenic specificity for a cancer-specific mutation
KR20170075785A (en) * 2014-11-05 2017-07-03 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Gene modified immune effector cells and engineered cells for expansion of immune effector cells
CN107223134B (en) * 2014-11-26 2021-11-16 美国卫生和人力服务部 T cell receptor for anti-mutated KRAS

Also Published As

Publication number Publication date
WO2019067242A1 (en) 2019-04-04
KR20200065026A (en) 2020-06-08
JP7391015B2 (en) 2023-12-04
AU2018342245A1 (en) 2020-04-16
IL273516A (en) 2020-05-31
CN111344394A (en) 2020-06-26
JP2020534839A (en) 2020-12-03
AU2018342245B2 (en) 2024-06-13
EP3688142A1 (en) 2020-08-05
US20200316121A1 (en) 2020-10-08
CA3080274A1 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
IL273516A (en) Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation
IL280738A (en) Methods, kits and apparatus for expanding a population of cells
DK3200818T3 (en) METHODS FOR ISOLATING T-CELL RECEPTORS WITH ANTIGEN SPECIFICITY TOWARDS A CANCER-SPECIFIC MUTATION
PL3444334T3 (en) Method for inducing antigen specific cd8 positive t cells
EP3142842A4 (en) Method of separating waste material
PL3481942T3 (en) Methods for culturing organoids
EP3219791A4 (en) Method for induction of t cells from pluripotent stem cells
EP3154555A4 (en) Method of producing leukocytes using ptpn2 inhibition for adoptive cell transfer
IL284690A (en) Process for preparing btk inhibitors
HK1252635A1 (en) Methods of preparing a primary cell sample
HK1246345A1 (en) Methods of culturing a mammalian cell
EP3134735A4 (en) Methods of measuring antigen-specific t cells
PL3119575T3 (en) Process for making isolating strips
EP3244901A4 (en) Methods for isolation of platelets
GB201608060D0 (en) Method of culturing T cells
SG10202007893TA (en) Methods of immunotherapy
EP3095875A4 (en) Luterial and method for isolating and culturing same
SG11201609269TA (en) Method of culturing cells
IL272403A (en) Methods for lysis of cells within a sample
EP3672590A4 (en) Methods for inducing hematopoietic stem cell specificity
PL3710400T3 (en) Process for reforming of methane
GB201416866D0 (en) Methods for providing a prognosis of pregnancy
AU2014901720A0 (en) Method of culturing cells
GB201413329D0 (en) Methods of obtaining islet cells
GB201408570D0 (en) Methods of obtaining islet cells